IDEXX Laboratories, Inc. (NASDAQ: IDXX), a number one pet healthcare firm, on Monday reported a rise in income and web earnings for the second quarter of fiscal 2025.
- Second-quarter income elevated to $1.11 billion from $1.0 billion within the prior-year quarter, up 11%
- On an natural foundation, income grew 9%, supported by CAG diagnostics recurring income progress of 9% as reported and seven% natural
- Internet earnings was $294.0 million in Q2 2025, in comparison with $203.3 million within the prior-year quarter
- Earnings, on a per-share foundation, climbed 49% year-over-year to $3.63 in Q2; EPS grew 17% on a comparable foundation
- The administration raised its full-year income steering to $4,205-4,280 million, a rise of $90 million or round 2% at midpoint
- The steering for full-year reported income progress is 7.7-9.7%; CAG diagnostics recurring income progress is anticipated to be 6.5-8.7%
- It expects full-year earnings to be within the vary of $12.40 per share to $12.76 per share
